Literature DB >> 32274708

Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.

Felipe C O B Teixeira1,2, Martin Götte3.   

Abstract

The cell surface heparan sulfate proteoglycan Syndecan-1 acts as an important co-receptor for receptor tyrosine kinases and chemokine receptors, and as an adhesion receptor for structural glycoproteins of the extracellular matrix. It serves as a substrate for heparanase, an endo-β-glucuronidase that degrades specific domains of heparan sulfate carbohydrate chains and thereby alters the functional status of the proteoglycan and of Syndecan-1-bound ligands. Syndecan-1 and heparanase show multiple levels of functional interactions, resulting in mutual regulation of their expression, processing, and activity. These interactions are of particular relevance in the context of inflammation and malignant disease. Studies in animal models have revealed a mechanistic role of Syndecan-1 and heparanase in the regulation of contact allergies, kidney inflammation, multiple sclerosis, inflammatory bowel disease, and inflammation-associated tumorigenesis. Moreover, functional interactions between Syndecan-1 and heparanase modulate virtually all steps of tumor progression as defined in the Hallmarks of Cancer. Due to their prognostic value in cancer, and their mechanistic involvement in tumor progression, Syndecan-1 and heparanase have emerged as important drug targets. Data in preclinical models and preclinical phase I/II studies have already yielded promising results that provide a translational perspective.

Entities:  

Keywords:  Growth factors; Inflammation; Mouse models; Signal transduction; Syndecan

Year:  2020        PMID: 32274708     DOI: 10.1007/978-3-030-34521-1_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  14 in total

Review 1.  Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.

Authors:  Sunil Rangarajan; Jillian R Richter; Robert P Richter; Shyam K Bandari; Kaushlendra Tripathi; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 2.  Targeting syndecan-1: new opportunities in cancer therapy.

Authors:  Zecheng Yang; Shuaitong Chen; Haoqiang Ying; Wantong Yao
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

Review 3.  Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis.

Authors:  Israel Vlodavsky; Uri Barash; Hien M Nguyen; Shi-Ming Yang; Neta Ilan
Journal:  Semin Thromb Hemost       Date:  2021-04-01       Impact factor: 6.398

Review 4.  Advances in the Immunomodulatory Properties of Glycoantigens in Cancer.

Authors:  Valeria da Costa; Teresa Freire
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

Review 5.  Syndecan-1 (CD138), Carcinomas and EMT.

Authors:  John R Couchman
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

6.  Heparanase as active player in endothelial glycocalyx remodeling.

Authors:  Valentina Masola; Nicola Greco; Giovanni Gambaro; Marco Franchi; Maurizio Onisto
Journal:  Matrix Biol Plus       Date:  2021-12-25

Review 7.  Syndecan receptors: pericellular regulators in development and inflammatory disease.

Authors:  Sandeep Gopal; Samantha Arokiasamy; Csilla Pataki; James R Whiteford; John R Couchman
Journal:  Open Biol       Date:  2021-02-10       Impact factor: 6.411

8.  Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells.

Authors:  Sofía Valla; Nourhan Hassan; Daiana Luján Vitale; Daniela Madanes; Fiorella Mercedes Spinelli; Felipe C O B Teixeira; Burkhard Greve; Nancy Adriana Espinoza-Sánchez; Carolina Cristina; Laura Alaniz; Martin Götte
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 9.  Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Authors:  Aikaterini Berdiaki; Monica Neagu; Eirini-Maria Giatagana; Andrey Kuskov; Aristidis M Tsatsakis; George N Tzanakakis; Dragana Nikitovic
Journal:  Biomolecules       Date:  2021-03-08

10.  Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes.

Authors:  Eyyad Nassar; Nourhan Hassan; Eslam A El-Ghonaimy; Hebatallah Hassan; Mahmoud Salah Abdullah; Theresa V Rottke; Ludwig Kiesel; Burkhard Greve; Sherif Abdelaziz Ibrahim; Martin Götte
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.